SEC Form 4 · accession 0000939767-18-000208
EXELIXIS, INC. · EXEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gisela Schwab
Officer — Pres, Prod Dev & Med Aff & CMO
Period of report
Oct 1, 2018
Accepted (ET)
Oct 3, 2018 · 8:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000939767
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 1, 2018 | M | 12,000 | $5.04 | A | 340,288 | D | |
| Common StockF3 | Oct 1, 2018 | S | 12,000 | $17.77 | D | 328,288 | D | |
| Common StockF4 | holding | — | — | — | 14,505 | I | By 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F5 | $5.04 | Oct 1, 2018 | M | 12,000 | D | Dec 16, 2009 | Dec 15, 2018 | Common Stock | 12,000 | 25,499 | D |
Explanation of responses
- F1Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- F2The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2018.
- F3Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.65 to $17.93. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
- F4Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of September 28, 2018.
- F5The option, representing the right to purchase a total of 50,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 16, 2012.